{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T18:31:40Z","timestamp":1782930700711,"version":"3.54.5"},"reference-count":146,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2023,2,22]],"date-time":"2023-02-22T00:00:00Z","timestamp":1677024000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>Allogeneic hematopoietic stem-cell transplantation (allo-HSCT) recipients are especially vulnerable to coronavirus disease 19 (COVID-19), because of their profound immunodeficiency. Indeed, the first pandemic wave was marked by a high mortality rate in this population. Factors increasing immunodepression such as older age, immunosuppressive treatments or a short delay between transplant and infection appear to worsen the prognosis. Many changes in clinical practice had to be implemented in order to limit this risk, including postponing of transplant for non-malignant diseases, preference for local rather than international donations and for peripheral blood as stem cell source, and the widespread use of cryopreservation. The great revolution in the COVID-19 pandemic came from the development of mRNA vaccines that have shown to be able to prevent severe forms of the disease. More than 75% of allo-HSCT recipients develop seroconversion after 2 doses of vaccine. Multiple studies have identified lymphopenia, exposure to immunosuppressive or anti-CD20 therapies, and a short post-transplant period as factors associated with a poor response to vaccination. The use of repeated injections of the vaccine, including a third dose, not only improves the seroconversion rate but also intensifies the immune response, both in B cells and T cells. Vaccines are an effective and well-tolerated method in this high-risk population. Some studies investigated the possibility of immune protection being transferred from a vaccinated donor to a recipient, with encouraging initial results. However, dynamic mutations and immune escape of the virus can lead to breakthrough infections with new variants in vaccinated individuals and still represent a threat of severe disease in allo-HSCT recipients. New challenges include the need to adapt vaccine protection to emerging variants.<\/jats:p>","DOI":"10.3389\/fimmu.2023.1100468","type":"journal-article","created":{"date-parts":[[2023,2,22]],"date-time":"2023-02-22T09:47:35Z","timestamp":1677059255000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":12,"title":["Allogeneic hematopoietic stem cell transplantation in the COVID-19 era"],"prefix":"10.3389","volume":"14","author":[{"given":"Jonathan","family":"Bordat","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S\u00e9bastien","family":"Maury","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mathieu","family":"Leclerc","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2023,2,22]]},"reference":[{"key":"B1","unstructured":"Coronavirus (COVID-19) dashboard"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-021-01302-5","article-title":"COVID-19 and stem cell transplantation; results from an EBMT and GETH multicenter prospective survey","volume":"35","author":"Ljungman","year":"2021","journal-title":"Leukemia"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-020-01019-x","article-title":"COVID-19 infection in hematopoietic cell transplantation: age, time from transplant and steroids matter","volume":"34","author":"Varma","year":"2020","journal-title":"Leukemia"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.17260","article-title":"Risk factors for a severe form of COVID-19 after allogeneic haematopoietic stem cell transplantation: a soci\u00e9t\u00e9 francophone de greffe de moelle et de th\u00e9rapie cellulaire (SFGM-TC) multicentre cohort study","volume":"192","author":"Xhaard","year":"2021","journal-title":"Br J Haematol"},{"key":"B5","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1186\/s40164-020-00177-z","article-title":"Risk factors and outcome of COVID-19 in patients with hematological malignancies","volume":"9","author":"Pi\u00f1ana","year":"2020","journal-title":"Exp Hematol Oncol"},{"key":"B6","doi-asserted-by":"publisher","first-page":"337.e1","DOI":"10.1016\/j.jtct.2022.03.010","article-title":"High mortality of COVID-19 early after allogeneic stem cell transplantation: A retrospective multicenter analysis on behalf of the German cooperative transplant study group","volume":"28","author":"Schaffrath","year":"2022","journal-title":"Transplant Cell Ther"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3026(20)30429-4","article-title":"Clinical characteristics and outcomes of COVID-19 in haematopoietic stem-cell transplantation recipients: An observational cohort study","volume":"8","author":"Sharma","year":"2021","journal-title":"Lancet Haematol"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-022-01578-1","article-title":"Recommendations for the management of COVID-19 in patients with haematological malignancies or haematopoietic cell transplantation, from the 2021 European conference on infections in leukaemia (ECIL 9)","volume":"36","author":"Cesaro","year":"2022","journal-title":"Leukemia"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2020008824","article-title":"Outcomes of patients with hematologic malignancies and COVID-19: a systematic review and meta-analysis of 3377 patients","volume":"136","author":"Vijenthira","year":"2020","journal-title":"Blood"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-020-2521-4","article-title":"Factors associated with COVID-19-related death using OpenSAFELY","volume":"584","author":"Williamson","year":"2020","journal-title":"Nature"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1038\/s41409-021-01312-y","article-title":"Clinical course and outcomes of COVID-19 in hematopoietic cell transplant patients, a regional report from the middle East","volume":"56","author":"El Fakih","year":"2021","journal-title":"Bone Marrow Transplant"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1111\/tid.13625","article-title":"Clinical presentation and outcomes of COVID-19 following hematopoietic cell transplantation and cellular therapy","volume":"23","author":"Camargo","year":"2021","journal-title":"Transpl Infect Dis"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1038\/s41409-020-01084-x","article-title":"COVID-19 in hematopoietic cell transplant recipients","volume":"56","author":"Altuntas","year":"2021","journal-title":"Bone Marrow Transplant"},{"key":"B14","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s12288-021-01472-3","article-title":"Outcomes of COVID-19 in hematopoietic stem cell transplant recipients: Multicenter retrospective analysis","volume":"38","author":"Agrawal","year":"2021","journal-title":"Indian J Hematol Blood Transfus"},{"key":"B15","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1186\/s13045-021-01177-0","article-title":"COVID-19 infection in adult patients with hematological malignancies: A European hematology association survey (EPICOVIDEHA)","volume":"14","author":"Pagano","year":"2021","journal-title":"J Hematol Oncol"},{"key":"B16","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1038\/s41591-022-01887-z","article-title":"Clinical outcomes among patients infected with omicron (B.1.1.529) SARS-CoV-2 variant in southern California","author":"Lewnard","year":"2022"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1136\/bmj-2021-069761","article-title":"Clinical severity of, and effectiveness of mRNA vaccines against, covid-19 from omicron, delta, and alpha SARS-CoV-2 variants in the united states: prospective observational study","volume":"376","author":"Lauring","year":"2022","journal-title":"BMJ"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(22)00462-7","article-title":"Comparative analysis of the risks of hospitalisation and death associated with SARS-CoV-2 omicron (B.1.1.529) and delta (B.1.617.2) variants in England: A cohort study","volume":"399","author":"Nyberg","year":"2022","journal-title":"Lancet"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2022.2274","article-title":"Estimates of SARS-CoV-2 omicron variant severity in Ontario, Canada","volume":"327","author":"Ulloa","year":"2022","journal-title":"JAMA"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(22)00327-0","article-title":"Symptom prevalence, duration, and risk of hospital admission in individuals infected with SARS-CoV-2 during periods of omicron and delta variant dominance: A prospective observational study from the ZOE COVID study","volume":"399","author":"Menni","year":"2022","journal-title":"Lancet"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(22)00141-4","article-title":"Severity of omicron variant of concern and vaccine effectiveness against symptomatic disease: National cohort with nested test negative design study in Scotland","volume":"22","author":"Sheikh","year":"2021","journal-title":"The Lancet Infectious Diseases"},{"key":"B22","doi-asserted-by":"crossref","DOI":"10.2139\/ssrn.4008930","article-title":"Reduced risk of hospitalisation associated with infection with SARS-CoV-2 omicron relative to delta: A Danish cohort study","volume-title":"Lancet Infect Dis","author":"Bager","year":"2022"},{"key":"B23","doi-asserted-by":"publisher","first-page":"2200077","DOI":"10.2807\/1560-7917.ES.2022.27.4.2200077","article-title":"Reduced risk of hospitalisation among reported COVID-19 cases infected with the SARS-CoV-2 omicron BA.1 variant compared with the delta variant, Norway, December 2021 to January 2022","volume":"27","author":"Veneti","year":"2022","journal-title":"Eurosurveillance"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.2139\/ssrn.3996320","article-title":"Clinical severity of COVID-19 patients admitted to hospitals in gauteng, south Africa during the omicron-dominant fourth wave","volume":"10","author":"Jassat","year":"2021","journal-title":"The Lancet Global Health"},{"key":"B25","doi-asserted-by":"crossref","DOI":"10.2139\/ssrn.4017381","article-title":"Omicron (BA.1) SARS-CoV-2 variant is associated with reduced risk of hospitalization and length of stay compared with delta (B.1.617.2)","volume-title":"Social Science Research Network","author":"Peralta-Santos","year":"2022"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccell.2022.02.012","article-title":"Impact of COVID-19 on case fatality rate of patients with cancer during the omicron wave","volume":"40","author":"Lee","year":"2022","journal-title":"Cancer Cell"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1038\/s41409-021-01287-w","article-title":"Changes in stem cell transplant activity and procedures during SARS-CoV2 pandemic in Italy: An Italian bone marrow transplant group (GITMO) nationwide analysis (TransCOVID-19 survey)","volume":"56","author":"Russo","year":"2021","journal-title":"Bone Marrow Transplant"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2020003883","article-title":"COVID-19 and hematopoietic stem cell transplantation and immune effector cell therapy: A US cancer center experience","volume":"5","author":"Maurer","year":"2021","journal-title":"Blood Adv"},{"key":"B29","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41409-022-01604-x","article-title":"Impact of the SARS-CoV-2 pandemic on hematopoietic cell transplantation and cellular therapies in Europe 2020: a report from the EBMT activity survey","volume":"57","author":"Passweg","year":"2022","journal-title":"Bone Marrow Transplant"},{"key":"B30","doi-asserted-by":"publisher","first-page":"798","DOI":"10.1038\/s41409-020-01138-0","article-title":"Stem cell donor registry activities during the COVID-19 pandemic: A field report by DKMS","volume":"56","author":"Mengling","year":"2021","journal-title":"Bone Marrow Transplant"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1038\/s41409-020-0919-0","article-title":"The challenge of COVID-19 and hematopoietic cell transplantation; EBMT recommendations for management of hematopoietic cell transplant recipients, their donors, and patients undergoing CAR T-cell therapy","volume":"55","author":"Ljungman","year":"2020","journal-title":"Bone Marrow Transplant"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3026(22)00293-9","article-title":"Haematopoietic stem-cell transplantation in China in the era of targeted therapies: Current advances, challenges, and future directions","volume":"9","author":"Chang","year":"2022","journal-title":"Lancet Haematology"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtct.2022.11.011","article-title":"Hematopoietic stem cell transplantation activity in China 2020\u20132021 during the SARS-CoV-2 pandemic: A report from the Chinese blood and marrow transplantation registry group","author":"Xu","year":"2022","journal-title":"Transplant Cell Ther"},{"key":"B34","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1016\/S0140-6736(20)30183-5","article-title":"Clinical features of patients infected with 2019 novel coronavirus in wuhan, China","volume":"395","author":"Huang","year":"2020","journal-title":"Lancet"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1111\/trf.16812","article-title":"Low rate of RNAemia in blood donations collected during the first wave of COVID-19 in France","volume":"62","author":"Le Cam","year":"2022","journal-title":"Transfusion"},{"key":"B36","doi-asserted-by":"publisher","first-page":"362","DOI":"10.2450\/2022.0266-21","article-title":"SARS-CoV-2 and post-donation information: A one-year experience of the French haemovigilance network","volume":"20","author":"Cappy","year":"2022","journal-title":"Blood Transfus"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2020008230","article-title":"No evidence of SARS-CoV-2 transfusion transmission despite RNA detection in blood donors showing symptoms after donation","volume":"136","author":"Cappy","year":"2020","journal-title":"Blood"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-020-04337-3","article-title":"Blood and platelet transfusion from a donor with presymptomatic covid-19","volume":"100","author":"Liapis","year":"2021","journal-title":"Ann Hematol"},{"key":"B39","doi-asserted-by":"publisher","first-page":"103129","DOI":"10.1016\/j.transci.2021.103129","article-title":"COVID-19 related callback in blood donors; outcomes in blood donors and patients","volume":"60","author":"Balagholi","year":"2021","journal-title":"Transfus Apher Sci"},{"key":"B40","doi-asserted-by":"publisher","first-page":"102961","DOI":"10.1016\/j.transci.2020.102961","article-title":"COVID-19: Further evidence of no transfusion transmission","volume":"60","author":"Luzzi","year":"2021","journal-title":"Transfus Apher Sci"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1159\/000515258","article-title":"Low prevalence of antibodies to SARS-CoV-2 and undetectable viral load in seropositive blood donors from south-Eastern Italy","volume":"144","author":"Di Stefano","year":"2021","journal-title":"Acta Haematol"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1002\/jha2.263","article-title":"No evidence of SARS-CoV-2 transmission through transfusion of human blood products: A systematic review","volume":"2","author":"Mawalla","year":"2021","journal-title":"EJHaem"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1016\/j.transci.2020.102921","article-title":"No transmission of SARS-CoV-2 in a patient undergoing allogeneic hematopoietic cell transplantation from a matched-related donor with unknown COVID-19","volume":"59","author":"del Campo","year":"2020","journal-title":"Transfusion Apheresis Sci"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1111\/trf.16056","article-title":"Risk of transmission of severe acute respiratory syndrome coronavirus 2 by transfusion: A literature review","volume":"60","author":"Leblanc","year":"2020","journal-title":"Transfusion"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3026(21)00025-9","article-title":"Allogeneic haematopoietic stem cell transplantation from SARS-CoV-2 positive donors","volume":"8","author":"Leclerc","year":"2021","journal-title":"Lancet Haematology"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1038\/s41409-020-0969-3","article-title":"Hematopoietic stem cell transplantation from an infected SARS-CoV2 donor sibling","volume":"55","author":"Anurathapan","year":"2020","journal-title":"Bone Marrow Transplant"},{"key":"B47","doi-asserted-by":"publisher","first-page":"102742","DOI":"10.1016\/j.transci.2020.102742","article-title":"Comparison of allogenic stem cell transplantations performed with frozen or fresh stem cell products with regard to GVHD and mortality","volume":"59","author":"Dagdas","year":"2020","journal-title":"Transfus Apher Sci"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1038\/bmt.2012.118","article-title":"Cryopreservation of allogeneic PBSC from related and unrelated donors is associated with delayed platelet engraftment but has no impact on survival","volume":"48","author":"Medd","year":"2013","journal-title":"Bone Marrow Transplant"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.26033","article-title":"Fresh vs. frozen allogeneic peripheral blood stem cell grafts: A successful timely option","volume":"96","author":"Alotaibi","year":"2021","journal-title":"Am J Hematol"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1111\/ejh.12140","article-title":"To freeze or not to freeze peripheral blood stem cells prior to allogeneic transplantation from matched related donors","volume":"91","author":"Parody","year":"2013","journal-title":"Eur J Haematology"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2007.07.003","article-title":"Similar outcomes of cryopreserved allogeneic peripheral stem cell transplants (PBSCT) compared to fresh allografts","volume":"13","author":"Kim","year":"2007","journal-title":"Biol Blood Marrow Transplant"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2020.04.001","article-title":"Graft cryopreservation does not impact overall survival after allogeneic hematopoietic cell transplantation using post-transplantation cyclophosphamide for graft-versus-Host disease prophylaxis","volume":"26","author":"Hamadani","year":"2020","journal-title":"Biol Blood Marrow Transplant"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2021005139","article-title":"Impact of cryopreservation and transit times of allogeneic grafts on hematopoietic and immune reconstitution","volume":"5","author":"Maurer","year":"2021","journal-title":"Blood Adv"},{"key":"B54","doi-asserted-by":"publisher","first-page":"215.e1","DOI":"10.1016\/j.jtct.2022.01.010","article-title":"Real-world experience of cryopreserved allogeneic hematopoietic grafts during the COVID-19 pandemic: A single-center report","volume":"28","author":"Bankova","year":"2022","journal-title":"Transplant Cell Ther"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2020.04.027","article-title":"Hematopoietic cell transplantation with cryopreserved grafts for severe aplastic anemia","volume":"26","author":"Eapen","year":"2020","journal-title":"Biol Blood Marrow Transplant"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtct.2021.03.015","article-title":"The effect of donor graft cryopreservation on allogeneic hematopoietic cell transplantation outcomes: A center for international blood and marrow transplant research analysis. implications during the COVID-19 pandemic","volume":"27","author":"Hsu","year":"2021","journal-title":"Transplant Cell Ther"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtct.2021.05.009","article-title":"Timely CIBMTR analysis of how cryopreservation impacts allogeneic hematopoietic cell transplantation to apply in the COVID era","volume":"27","author":"Allan","year":"2021","journal-title":"Transplant Cell Ther"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-1759(03)00202-3","article-title":"Effects of cryopreservation on lymphocyte immunophenotype and function","volume":"278","author":"Costantini","year":"2003","journal-title":"J Immunol Methods"},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.1038\/bmt.2008.93","article-title":"Transportation and cryopreservation may impair haematopoietic stem cell function and engraftment of allogeneic PBSCs, but not BM","volume":"42","author":"Lioznov","year":"2008","journal-title":"Bone Marrow Transplant"},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2020002431","article-title":"Variable CD34+ recovery of cryopreserved allogeneic HPC products: Transplant implications during the COVID-19 pandemic","volume":"4","author":"Purtill","year":"2020","journal-title":"Blood Adv"},{"key":"B61","article-title":"A meta-analysis of early results to predict vaccine efficacy against omicron","volume-title":"Blood Advances","author":"Khoury","year":"2020"},{"key":"B62","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2034577","article-title":"Safety and efficacy of the BNT162b2 mRNA covid-19 vaccine","volume":"383","author":"Polack","year":"2020","journal-title":"N Engl J Med"},{"key":"B63","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2035389","article-title":"Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine","volume":"384","author":"Baden","year":"2021","journal-title":"N Engl J Med"},{"key":"B64","doi-asserted-by":"publisher","DOI":"10.1002\/jmv.27503","article-title":"Detection of highly muted coronavirus variant omicron (B.1.1.529) is triggering the alarm for south Asian countries: Associated risk factors and preventive actions","volume":"94","author":"Daria","year":"2022","journal-title":"J Med Virol"},{"key":"B65","doi-asserted-by":"publisher","DOI":"10.26434\/chemrxiv-2021-n23f5","article-title":"The effect of the multiple mutations in omicron RBD on its binding to human ACE2 receptor and immune evasion: An investigation of molecular dynamics simulations","volume":"94","author":"Wu","year":"20221","journal-title":"Journal of Medical Virology"},{"key":"B66","doi-asserted-by":"publisher","DOI":"10.1002\/jmv.27539","article-title":"Roles of the polybasic furin cleavage site of spike protein in SARS-CoV-2 replication, pathogenesis, and host immune responses and vaccination","volume":"94","author":"Hossain","year":"2022","journal-title":"J Med Virol"},{"key":"B67","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1016\/j.cell.2021.12.033","article-title":"mRNA-based COVID-19 vaccine boosters induce neutralizing immunity against SARS-CoV-2 omicron variant","volume":"185","author":"Garcia-Beltran","year":"2022","journal-title":"Cell"},{"key":"B68","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(22)00090-3","article-title":"Breakthrough infections with SARS-CoV-2 omicron despite mRNA vaccine booster dose","volume":"399","author":"Kuhlmann","year":"2022","journal-title":"Lancet"},{"key":"B69","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2118691","article-title":"Protection against SARS-CoV-2 after covid-19 vaccination and previous infection","volume":"386","author":"Hall","year":"2022","journal-title":"New Engl J Med"},{"key":"B70","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2026116","article-title":"Humoral immune response to SARS-CoV-2 in Iceland","volume":"383","author":"Gudbjartsson","year":"2020","journal-title":"New Engl J Med"},{"key":"B71","doi-asserted-by":"publisher","DOI":"10.1038\/s41423-021-00708-6","article-title":"Dynamics of the SARS-CoV-2 antibody response up to 10 months after infection","volume":"18","author":"Wang","year":"2021","journal-title":"Cell Mol Immunol"},{"key":"B72","doi-asserted-by":"publisher","DOI":"10.1126\/science.abf4063","article-title":"Immunological memory to SARS-CoV-2 assessed for up to 8 months after infection","volume":"371","author":"Dan","year":"2021","journal-title":"Science"},{"key":"B73","doi-asserted-by":"publisher","DOI":"10.1126\/science.abf4063","article-title":"Immunological memory to SARS-CoV-2 assessed for up to 8 months after infection","volume":"371","author":"Dan","year":"2021","journal-title":"Science"},{"key":"B74","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2021014232","article-title":"Antibody response after 2 and 3 doses of SARS-CoV-2 mRNA vaccine in allogeneic hematopoietic cell transplant recipients","volume":"139","author":"Maillard","year":"2022","journal-title":"Blood"},{"key":"B75","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(21)01594-4","article-title":"Antibody response after second BNT162b2 dose in allogeneic HSCT recipients","volume":"398","author":"Redjoul","year":"2021","journal-title":"Lancet"},{"key":"B76","doi-asserted-by":"publisher","DOI":"10.1007\/s12185-022-03325-9","article-title":"Antibody response to COVID-19 vaccine in 130 recipients of hematopoietic stem cell transplantation","volume":"115","author":"Tsushima","year":"2022","journal-title":"Int J Hematol"},{"key":"B77","doi-asserted-by":"publisher","first-page":"e13828","DOI":"10.1111\/tid.13828","article-title":"Antibody response to mRNA SARS-CoV-2 vaccination in 182 patients after allogeneic hematopoietic cell transplantation","volume":"24","author":"Beerlage","year":"2022","journal-title":"Transplant Infect Dis"},{"key":"B78","doi-asserted-by":"publisher","first-page":"214.e1","DOI":"10.1016\/j.jtct.2022.01.019","article-title":"Antibody response to SARS-CoV-2 vaccination in patients following allogeneic hematopoietic cell transplantation","volume":"28","author":"Huang","year":"2022","journal-title":"Transplant Cell Ther"},{"key":"B79","doi-asserted-by":"publisher","DOI":"10.1038\/s41409-021-01466-9","article-title":"Antibody responses to SARS-CoV2 vaccination in allogeneic hematopoietic stem cell transplant recipients","volume":"56","author":"Mamez","year":"2021","journal-title":"Bone Marrow Transplant"},{"key":"B80","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtct.2022.02.018","article-title":"B cell aplasia is the most powerful predictive marker for poor humoral response after BNT162b2 mRNA SARS-CoV-2 vaccination in recipients of allogeneic hematopoietic stem cell transplantation","volume":"28","author":"Jullien","year":"2022","journal-title":"Transplant Cell Ther"},{"key":"B81","doi-asserted-by":"publisher","first-page":"330","DOI":"10.3390\/vaccines10020330","article-title":"Humoral responses and chronic GVHD exacerbation after COVID-19 vaccination post allogeneic stem cell transplantation","volume":"10","author":"Pabst","year":"2022","journal-title":"Vaccines"},{"key":"B82","doi-asserted-by":"publisher","first-page":"4876","DOI":"10.1182\/blood-2021-149979","article-title":"Humoral serologic response to the BNT162b2 vaccine afterallogeneic haematopoietic cell transplantation","volume":"138","author":"Yeshurun","year":"2021","journal-title":"Blood"},{"key":"B83","doi-asserted-by":"publisher","first-page":"4876","DOI":"10.1016\/j.jtct.2022.06.012","article-title":"Predictors of covid-19 vaccination response after in-vivo T-cell depleted stem cell transplantation","volume":"138","author":"Chaekal","year":"2022","journal-title":"Transplant Cell Ther"},{"key":"B84","doi-asserted-by":"publisher","DOI":"10.1158\/2643-3230.BCD-21-0142","article-title":"Predictors of humoral response to SARS-CoV-2 vaccination after hematopoietic cell transplantation and CAR T-cell therapy","volume":"2","author":"Tamari","year":"2021","journal-title":"Blood Cancer Discovery"},{"key":"B85","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1186\/s13045-021-01190-3","article-title":"Predictors of neutralizing antibody response to BNT162b2 vaccination in allogeneic hematopoietic stem cell transplant recipients","volume":"14","author":"Canti","year":"2021","journal-title":"J Hematol Oncol"},{"key":"B86","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41408-021-00605-1","article-title":"Robust COVID-19 vaccination response after allogeneic stem cell transplantation using post transplantation cyclophosphamide conditioning","volume":"12","author":"Morsink","year":"2022","journal-title":"Blood Cancer J"},{"key":"B87","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2021.26344","article-title":"Safety and antibody response after 1 and 2 doses of BNT162b2 mRNA vaccine in recipients of allogeneic hematopoietic stem cell transplant","volume":"4","author":"Le Bourgeois","year":"2021","journal-title":"JAMA Network Open"},{"key":"B88","doi-asserted-by":"publisher","DOI":"10.1002\/jha2.242","article-title":"Safety and immunogenicity of a first dose of SARS-CoV-2 mRNA vaccine in allogeneic hematopoietic stem-cells recipients","volume":"2","author":"Chevallier","year":"2021","journal-title":"eJHaem"},{"key":"B89","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1002\/ajh.26385","article-title":"SARS-CoV-2-reactive antibody detection after SARS-CoV-2 vaccination in hematopoietic stem cell transplant recipients: Prospective survey from the Spanish hematopoietic stem cell transplantation and cell therapy group","volume":"97","author":"Pi\u00f1ana","year":"2022","journal-title":"Am J Hematol"},{"key":"B90","doi-asserted-by":"publisher","first-page":"158","DOI":"10.3390\/vaccines10020158","article-title":"The safety and immunogenicity of the BNT162b2 mRNA COVID-19 vaccine in Japanese patients after allogeneic stem cell transplantation","volume":"10","author":"Watanabe","year":"2022","journal-title":"Vaccines"},{"key":"B91","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtct.2021.07.008","article-title":"Safety and tolerability of SARS-CoV2 emergency-use authorized vaccines for allogeneic hematopoietic stem cell transplant recipients","volume":"27","author":"Ali","year":"2021","journal-title":"Transplant Cell Ther"},{"key":"B92","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3026(21)00274-X","article-title":"Antibody response after third BNT162b2 dose in recipients of allogeneic HSCT","volume":"8","author":"Redjoul","year":"2021","journal-title":"Lancet Haematol"},{"key":"B93","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccell.2022.02.010","article-title":"Efficacy of a third SARS-CoV-2 mRNA vaccine dose among hematopoietic cell transplantation, CAR T cell, and BiTE recipients","volume":"40","author":"Abid","year":"2022","journal-title":"Cancer Cell"},{"key":"B94","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.17911","article-title":"Interest of a third dose of BNT162b2 anti-SARS-CoV-2 messenger RNA vaccine after allotransplant","volume":"196","author":"Le Bourgeois","year":"2022","journal-title":"Br J Haematology"},{"key":"B95","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccell.2022.02.005","article-title":"Antibody response against SARS-CoV-2 delta and omicron variants after third-dose BNT162b2 vaccination in allo-HSCT recipients","volume":"40","author":"Canti","year":"2022","journal-title":"Cancer Cell"},{"key":"B96","doi-asserted-by":"publisher","DOI":"10.1002\/hon.3006","article-title":"Effectiveness of a third dose of BNT162b2 anti-SARS-CoV-2 mRNA vaccine over a 6-month follow-up period in allogenic hematopoietic stem cells recipients","volume":"40","author":"Chevallier","year":"2022","journal-title":"Hematol Oncol"},{"key":"B97","doi-asserted-by":"publisher","first-page":"706.e1","DOI":"10.1016\/j.jtct.2022.07.024","article-title":"Safety and immunogenicity after a three-dose SARS-CoV-2 vaccine schedule in allogeneic stem cell transplant recipients","volume":"28","author":"Kimura","year":"2022","journal-title":"Transplant Cell Therapy Off Publ Am Soc Transplant Cell Ther"},{"key":"B98","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1186\/s13045-022-01250-2","article-title":"Determinants of SARS-CoV-2 waning immunity in allogeneic hematopoietic stem cell transplant recipients","volume":"15","author":"Leclerc","year":"2022","journal-title":"J Hematol Oncol"},{"key":"B99","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-021-01386-7","article-title":"CD8+ T cells contribute to survival in patients with COVID-19 and hematologic cancer","volume":"27","author":"Bange","year":"2021","journal-title":"Nat Med"},{"key":"B100","doi-asserted-by":"publisher","DOI":"10.1038\/s41590-021-01122-w","article-title":"The T cell immune response against SARS-CoV-2","volume":"23","author":"Moss","year":"2022","journal-title":"Nat Immunol"},{"key":"B101","doi-asserted-by":"publisher","first-page":"100081","DOI":"10.1016\/j.xcrm.2020.100081","article-title":"SARS-CoV-2-Specific T cells exhibit phenotypic features of helper function, lack of terminal differentiation, and high proliferation potential","volume":"1","author":"Neidleman","year":"2020","journal-title":"Cell Rep Med"},{"key":"B102","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2021006937","article-title":"Deficiency of SARS-CoV-2 T-cell responses after vaccination in long-term allo-HSCT survivors translates into abated humoral immunity","volume":"6","author":"Einarsdottir","year":"2022","journal-title":"Blood Adv"},{"key":"B103","doi-asserted-by":"publisher","DOI":"10.1016\/j.xcrm.2020.100081","article-title":"Impaired humoral and cellular response to primary COVID-19 vaccination in patients less than 2 years after allogeneic bone marrow transplant","volume":"1","author":"Murray","year":"2020","journal-title":"Br J Haematology"},{"key":"B104","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccell.2021.10.002","article-title":"Repeated vaccination against SARS-CoV-2 elicits robust polyfunctional T cell response in allogeneic stem cell transplantation recipients","volume":"39","author":"Harrington","year":"2021","journal-title":"Cancer Cell"},{"key":"B105","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1186\/s13045-022-01300-9","article-title":"Immune response to vaccination against SARS-CoV-2 in hematopoietic stem cell transplantation and CAR T-cell therapy recipients","volume":"15","author":"Wu","year":"2022","journal-title":"J Hematol Oncol"},{"key":"B106","article-title":"BNT162b2 vaccination induces durable SARS-CoV-2\u2013specific T cells with a stem cell memory phenotype","volume-title":"Cancer Cell","year":""},{"key":"B107","doi-asserted-by":"publisher","DOI":"10.1002\/eji.202149771","article-title":"SARS-CoV-2-specific T cells are generated in less than half of allogeneic HSCT recipients failing to seroconvert after COVID-19 vaccination","author":"Jarisch","year":"2022","journal-title":"Eur J Immunol"},{"key":"B108","doi-asserted-by":"publisher","DOI":"10.1126\/sciimmunol.abl5344","article-title":"Reduced antibodies and innate cytokine changes in SARS-CoV-2 BNT162b2 mRNA vaccinated transplant patients with hematological malignancies","volume":"13","author":"Bergamaschi","year":"2022","journal-title":"Front Immunol"},{"key":"B109","doi-asserted-by":"publisher","first-page":"1041","DOI":"10.1016\/j.cell.2022.01.029","article-title":"T Cell reactivity to the SARS-CoV-2 omicron variant is preserved in most but not all individuals","volume":"185","author":"Naranbhai","year":"2022","journal-title":"Cell"},{"key":"B110","doi-asserted-by":"publisher","first-page":"3998","DOI":"10.1002\/jmv.27814","article-title":"T-Cell responses to SARS-CoV-2 omicron spike epitopes with mutations after the third booster dose of an inactivated vaccine","volume":"94","author":"Li","year":"2022","journal-title":"J Med Virol"},{"key":"B111","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.17918","article-title":"Immunogenicity and safety of the BNT162b2 mRNA COVID-19 vaccine in haematopoietic stem cell transplantation recipients","volume":"196","author":"Shem-Tov","year":"2022","journal-title":"Br J Haematology"},{"key":"B112","doi-asserted-by":"publisher","first-page":"ciab930","DOI":"10.1093\/cid\/ciab930","article-title":"Severe acute respiratory syndrome coronavirus 2 messenger RNA vaccines in allogeneic hematopoietic stem cell transplant recipients: Immunogenicity and reactogenicity","volume":"94","author":"Sherman","year":"2021","journal-title":"Clin Infect Dis"},{"key":"B113","doi-asserted-by":"publisher","first-page":"1209","DOI":"10.3390\/vaccines9101209","article-title":"The COVID-19 mRNA BNT163b2 vaccine was well tolerated and highly immunogenic in young adults in long follow-up after haematopoietic stem cell transplantation","volume":"9","author":"Matkowska-Kocjan","year":"2021","journal-title":"Vaccines"},{"key":"B114","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtct.2021.06.024","article-title":"Safety and immunogenicity of the BNT162b2 mRNA COVID-19 vaccine in patients after allogeneic HSCT or CD19-based CART therapy\u2013a single-center prospective cohort study","volume":"27","author":"Ram","year":"2021","journal-title":"Transplant Cell Ther"},{"key":"B115","doi-asserted-by":"publisher","first-page":"1013","DOI":"10.3390\/vaccines9091013","article-title":"Varicella zoster virus reactivation following COVID-19 vaccination: A systematic review of case reports","volume":"9","author":"Katsikas Triantafyllidis","year":"2021","journal-title":"Vaccines"},{"key":"B116","doi-asserted-by":"publisher","DOI":"10.1111\/ijd.15001","article-title":"Herpes zoster in COVID-19-positive patients","volume":"59","author":"Tartari","year":"2020","journal-title":"Int J Dermatol"},{"key":"B117","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V87.7.3012.bloodjournal8773012","article-title":"Donor immunization with haemophilus influenzae type b (HIB)-conjugate vaccine in allogeneic bone marrow transplantation","volume":"87","author":"Molrine","year":"1996","journal-title":"Blood"},{"key":"B118","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bmt.1704336","article-title":"Efficacy of donor vaccination before hematopoietic cell transplantation and recipient vaccination both before and early after transplantation","volume":"33","author":"Storek","year":"2004","journal-title":"Bone Marrow Transplant"},{"key":"B119","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2002-03-0832","article-title":"Donor immunization with pneumococcal conjugate vaccine and early protective antibody responses following allogeneic hematopoietic cell transplantation","volume":"101","author":"Molrine","year":"2003","journal-title":"Blood"},{"key":"B120","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bmt.1705562","article-title":"A randomized study on donor immunization with tetanus\u2013diphtheria, haemophilus influenzae type b and inactivated poliovirus vaccines to improve the recipient responses to the same vaccines after allogeneic bone marrow transplantation","volume":"39","author":"Parkkali","year":"2007","journal-title":"Bone Marrow Transplant"},{"key":"B121","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3026(22)00097-7","article-title":"Impact of donor vaccination on recipient response to early SARS-CoV-2 mRNA vaccination after allogeneic HSCT","volume":"9","author":"Leclerc","year":"2022","journal-title":"Lancet Haematol"},{"key":"B122","doi-asserted-by":"publisher","DOI":"10.1002\/jha2.398","article-title":"Anti-SARS-CoV-2 vaccines in recipient and\/or donor before allotransplant","volume":"101","author":"Jullien","year":"2022","journal-title":"EJHaem 10.1002\/jha2.398"},{"key":"B123","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.26691","article-title":"Adoptive transfer of functional SARS-COV-2-specific immunity from donor graft to hematopoietic stem cell transplant recipients","volume":"97","author":"La Rosa","year":"2022","journal-title":"Am J Hematol"},{"key":"B124","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2021.24939","article-title":"Effect of subcutaneous casirivimab and imdevimab antibody combination vs placebo on development of symptomatic COVID-19 in early asymptomatic SARS-CoV-2 infection: A randomized clinical trial","volume":"327","author":"O\u2019Brien","year":"2022","journal-title":"JAMA"},{"key":"B125","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(22)00163-5","article-title":"Casirivimab and imdevimab in patients admitted to hospital with COVID-19 (RECOVERY): A randomised, controlled, open-label, platform trial","volume":"399","author":"Abani","year":"2022","journal-title":"Lancet"},{"key":"B126","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2107934","article-title":"Early treatment for covid-19 with SARS-CoV-2 neutralizing antibody sotrovimab","volume":"385","author":"Gupta","year":"2021","journal-title":"N Engl J Med"},{"key":"B127","doi-asserted-by":"publisher","first-page":"ofac053","DOI":"10.1093\/ofid\/ofac053","article-title":"Efficacy and safety of regdanvimab (CT-P59): A phase 2\/3 randomized, double-blind, placebo-controlled trial in outpatients with mild-to-Moderate coronavirus disease 2019","volume":"9","author":"Streinu-Cercel","year":"2022","journal-title":"Open Forum Infect Dis"},{"key":"B128","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-2600(22)00180-1","article-title":"Efficacy and safety of intramuscular administration of tixagevimab\u2013cilgavimab for early outpatient treatment of COVID-19 (TACKLE): A phase 3, randomised, double-blind, placebo-controlled trial","volume":"10","author":"Montgomery","year":"2022","journal-title":"Lancet Respir Med"},{"key":"B129","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2116620","article-title":"Intramuscular AZD7442 (Tixagevimab\u2013cilgavimab) for prevention of covid-19","volume":"386","author":"Levin","year":"2022","journal-title":"N Engl J Med"},{"key":"B130","doi-asserted-by":"publisher","first-page":"118","DOI":"10.3390\/diseases10040118","article-title":"Efficacy and safety of Tixagevimab\/Cilgavimab to prevent COVID-19 (Pre-exposure prophylaxis): A systematic review and meta-analysis","volume":"10","author":"Alhumaid","year":"2022","journal-title":"Diseases"},{"key":"B131","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2022018283","article-title":"Efficacy of tixagevimab-cilgavimab in preventing SARS-CoV-2 for patients with b-cell malignancies","volume":"141","author":"Davis","year":"2023","journal-title":"Blood"},{"key":"B132","doi-asserted-by":"publisher","DOI":"10.14740\/jh1062","article-title":"Real-world effectiveness of tixagevimab and cilgavimab (Evusheld) in patients with hematological malignancies","volume":"11","author":"Ocon","year":"2022","journal-title":"J Hematol"},{"key":"B133","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1186\/s13045-022-01387-0","article-title":"Pre-exposure prophylaxis with tixagevimab\/cilgavimab (AZD7442) prevents severe SARS-CoV-2 infection in recipients of allogeneic hematopoietic stem cell transplantation during the omicron wave: A multicentric retrospective study of SFGM-TC","volume":"15","author":"Jondreville","year":"2022","journal-title":"J Hematol Oncol"},{"key":"B134","doi-asserted-by":"publisher","DOI":"10.1128\/spectrum.04103-22","article-title":"Sotrovimab in hospitalized patients with SARS-CoV-2 omicron variant infection: A propensity score-matched retrospective cohort study","author":"Woo","year":"2022","journal-title":"Microbiol Spectr"},{"key":"B135","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-022-01792-5","article-title":"Serum neutralization of SARS-CoV-2 omicron sublineages BA.1 and BA.2 in patients receiving monoclonal antibodies","volume":"28","author":"Bruel","year":"2022","journal-title":"Nat Med"},{"key":"B136","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-021-04385-3","article-title":"Omicron escapes the majority of existing SARS-CoV-2 neutralizing antibodies","volume":"602","author":"Cao","year":"2022","journal-title":"Nature"},{"key":"B137","doi-asserted-by":"publisher","first-page":"12609","DOI":"10.1038\/s41598-022-16964-z","article-title":"In vitro activity of therapeutic antibodies against SARS-CoV-2 omicron BA.1, BA.2 and BA.5","volume":"12","author":"Touret","year":"2022","journal-title":"Sci Rep"},{"key":"B138","doi-asserted-by":"publisher","first-page":"1999","DOI":"10.3390\/v14091999","article-title":"A critical analysis of the use of cilgavimab plus tixagevimab monoclonal antibody cocktail (EvusheldTM) for COVID-19 prophylaxis and treatment","volume":"14","author":"Focosi","year":"2022","journal-title":"Viruses"},{"key":"B139","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-022-04594-4","article-title":"Antibody evasion properties of SARS-CoV-2 omicron sublineages","volume":"604","author":"Iketani","year":"2022","journal-title":"Nature"},{"key":"B140","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(22)00365-6","article-title":"Neutralisation sensitivity of SARS-CoV-2 omicron subvariants to therapeutic monoclonal antibodies","volume":"22","author":"Yamasoba","year":"2022","journal-title":"Lancet Infect Dis"},{"key":"B141","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMc2207519","article-title":"Efficacy of antibodies and antiviral drugs against omicron BA.2.12.1, BA.4, and BA.5 subvariants","volume":"387","author":"Takashita","year":"2022","journal-title":"New Engl J Med"},{"key":"B142","unstructured":"EVUSHELD (tixag\u00e9vimab\/cilgavimab) - COVID-19. haute autorit\u00e9 de sant\u00e9"},{"key":"B143","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2118542","article-title":"Oral nirmatrelvir for high-risk, nonhospitalized adults with covid-19","volume":"386","author":"Hammond","year":"2022","journal-title":"N Engl J Med"},{"key":"B144","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2007764","article-title":"Remdesivir for the treatment of covid-19 \u2014 final report","volume":"383","author":"Beigel","year":"2020","journal-title":"N Engl J Med"},{"key":"B145","doi-asserted-by":"publisher","DOI":"10.1080\/10428194.2021.1966782","article-title":"COVID-19 among patients with hematological malignancies: A national Israeli retrospective analysis with special emphasis on treatment and outcome","volume":"62","author":"Levy","year":"2021","journal-title":"Leuk Lymphoma"},{"key":"B146","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1056\/NEJMoa2021436","article-title":"Dexamethasone in hospitalized patients with covid-19","volume":"384","year":"2021","journal-title":"N Engl J Med"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2023.1100468\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,2,22]],"date-time":"2023-02-22T09:47:46Z","timestamp":1677059266000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2023.1100468\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,2,22]]},"references-count":146,"alternative-id":["10.3389\/fimmu.2023.1100468"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2023.1100468","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,2,22]]},"article-number":"1100468"}}